抑制IL-10R可重编程肿瘤相关巨噬细胞并逆转多发性骨髓瘤耐药
研究探讨IL-10在多发性骨髓瘤(MM)肿瘤相关巨噬细胞(TAM)发育中的作用及靶向IL-10/IL-10R/STAT3信号的治疗潜力。结果显示MM骨髓中IL-10过表达并介导TAM的M2样极化,TAM促进MM增殖和耐药;阻断IL-10R或降解STAT3可阻止M2极化、抑制TAM诱导的增殖并逆转耐药。作者认为该轴抑制是具单药疗效且可与免疫调节药物联合的新策略,但需未来研究在MM患者中评估。
要点
- MM骨髓中IL-10过表达,介导TAM的M2样极化。
- TAM促进MM增殖和耐药,体外和体内均如此。
- 阻断IL-10/IL-10R/STAT3轴可阻止M2极化并逆转耐药。
核心结论
- 抑制IL-10/IL-10R/STAT3轴是具单药疗效的新治疗策略,可进一步与免疫调节药物等现有抗MM治疗联合以克服耐药。
- 未来需开展研究评估该疗法在MM患者中的潜力。
研究设计与样本
- 研究采用患者骨髓样本、体外3D共培养和小鼠模型,探讨IL-10在MM TAM发育中的作用及IL-10/IL-10R/STAT3信号抑制的治疗应用。
主要发现
- IL-10在MM骨髓中过表达,并在患者骨髓、体外3D共培养和小鼠模型中介导TAM的M2样极化。
- TAM在体外和体内均促进MM增殖和耐药。
- 使用阻断性IL-10R单克隆抗体和STAT3蛋白降解剂/PROTAC抑制IL-10/IL-10R/STAT3轴,在体外和体内阻止TAM的M2极化及TAM诱导的MM增殖,并使MM重新对治疗敏感。
临床怎么用
- 作者认为抑制IL-10/IL-10R/STAT3轴是具单药疗效的新治疗策略,可进一步与免疫调节药物等现有抗MM治疗联合以克服耐药。
- 作者提出未来需开展研究评估该疗法在MM患者中的潜力。
局限性
- 未来需开展研究评估该疗法在MM患者中的潜力。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Multiple myeloma (MM) is the cancer of plasma cells within the bone marrow and remains incurable. Tumor-associated macrophages (TAMs) within the tumor microenvironment often display a pro-tumor phenotype and correlate with tumor proliferation, survival, and therapy resistance. IL-10 is a key immunosuppressive cytokine that leads to recruitment and development of TAMs. In this study, we investigated the role of IL-10 in MM TAM development as well as the therapeutic application of IL-10/IL-10R/STAT3 signaling inhibition. We demonstrated that IL-10 is overexpressed in MM BM and mediates M2-like polarization of TAMs in patient BM, 3D co-cultures in vitro, and mouse models. In turn, TAMs promote MM proliferation and drug resistance, both in vitro and in vivo. Moreover, inhibition of IL-10/IL-10R/STAT3 axis using a blocking IL-10R monoclonal antibody and STAT3 protein degrader/PROTAC prevented M2 polarization of TAMs and the consequent TAM-induced proliferation of MM, and re-sensitized MM to therapy, in vitro and in vivo. Therefore, our findings suggest that inhibition of IL-10/IL-10R/STAT3 axis is a novel therapeutic strategy with monotherapy efficacy and can be further combined with current anti-MM therapy, such as immunomodulatory drugs, to overcome drug resistance. Future investigation is warranted to evaluate the potential of such therapy in MM patients.
引用
- Sun J, Corradini S, Azab F, et al. IL-10R inhibition reprograms tumor-associated macrophages and reverses drug resistance in multiple myeloma. Leukemia. 2024. PMID: 39215060. doi:10.1038/s41375-024-02391-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。